Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study - Wikidata - wikimedia - TriplyDB

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

http://www.wikidata.org/entity/Q59129064

about

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study

http://www.wikidata.org/entity/Q59129064

description

article publié dans la revue scientifique Scientific Reports

@fr

im September 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published in Scientific Reports

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Prognostic Value of Tumor Hete ...... estrant: a retrospective study

@en

Prognostic Value of Tumor Hete ...... estrant: a retrospective study

@nl

type

label

Prognostic Value of Tumor Hete ...... estrant: a retrospective study

@en

Prognostic Value of Tumor Hete ...... estrant: a retrospective study

@nl

prefLabel

Prognostic Value of Tumor Hete ...... estrant: a retrospective study

@en

Prognostic Value of Tumor Hete ...... estrant: a retrospective study

@nl

P1433

Q59129064-3D0D9595-DDC0-4D40-93FB-3579CB29C903

P1476

Q59129064-B363077F-CFA4-4363-9B2F-127E2E53D76D

P2093

Q59129064-0A79C2B5-6D48-477A-9547-6A129CB883A1

Q59129064-1353E87D-9707-4EEE-8F4A-860FB566E72F

Q59129064-527E0DE1-511C-46A4-B557-537D24C4CCFC

Q59129064-7E62486B-72AA-4B44-8305-3C817BB075F3

Q59129064-8753A938-62FE-4CF9-AAC7-0B70F6F051FF

Q59129064-9DB7E437-F002-41C8-A919-028AAF9D9668

Q59129064-A78F8377-70EB-4D70-99C5-05CF2822976E

Q59129064-B10E0024-3061-4944-B4FA-49A6026BB6BD

Q59129064-D7C37843-A6EB-4194-84D4-E61934A8B696

P2860

Q59129064-1DDA0D8A-2A54-4918-9DAA-826E667E25AC

Q59129064-284D569A-CF49-4D04-BAF4-04CA4DA11B9A

Q59129064-30850F03-15DA-4A0D-BE46-9DC8EE0B1C48

Q59129064-41C46DB7-B64C-4020-A287-6B692DFFFB3C

Q59129064-48CA301A-B774-4D96-8801-2E113035DC44

Q59129064-4D36C605-83AA-4D9C-96F8-A8CE0E114B60

Q59129064-53E4C1D5-E4E4-431A-831C-01DE090DB365

Q59129064-82566894-ACE2-45CD-9DE1-4C30C42C2E6E

Q59129064-90E2F124-73A0-4925-A8C2-8609BC5C56AD

Q59129064-9417944C-08EA-4D32-A21B-B68DBCC70EB5

P304

Q59129064-CCBC67B9-ECFF-4FE7-8014-8DCC7FA067DF

P31

Q59129064-2333EA52-CD37-4C54-BE85-B97F705EF3C3

P356

Q59129064-F671FB65-4848-4829-829E-BE001E5F2FE7

P407

Q59129064-68C70809-A6D3-48BC-BC38-E4CA60E003B9

P433

Q59129064-1AFA0B12-3B12-4BC3-A8EE-7DE1E6D3C0B4

P478

Q59129064-08ED5BCE-EA65-45F9-BD71-68648D4D2D0B

P577

Q59129064-B53847D3-4DC0-4EDE-B92B-E7C8B458B9C3

P698

Q59129064-A2A144E2-A4AD-41D8-A43E-3279B54250FC

P932

Q59129064-4232A388-26EF-4622-87F3-AB0316C767DE

P356

S41598-018-32745-Z

P1433

Scientific Reports

P1476

Prognostic Value of Tumor Hete ...... estrant: a retrospective study

@en

P2093

Bingrui Wu

http://www.w3.org/2001/XMLSchema#string

Biyun Wang

http://www.w3.org/2001/XMLSchema#string

Cheng Liu

http://www.w3.org/2001/XMLSchema#string

Chengcheng Gong

http://www.w3.org/2001/XMLSchema#string

Yannan Zhao

http://www.w3.org/2001/XMLSchema#string

Yi Li

http://www.w3.org/2001/XMLSchema#string

Yingjian Zhang

http://www.w3.org/2001/XMLSchema#string

Yizhao Xie

http://www.w3.org/2001/XMLSchema#string

Zhongyi Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor heterogeneity: causes and consequences

FDG PET/CT imaging of oropharyngeal squamous cell carcinoma: characteristics of human papillomavirus-positive and -negative tumors

A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China.

Pretreatment (18)F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma--a retrospective study

Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer.

Estrogen modulates metabolic pathway adaptation to available glucose in breast cancer cells

(18)F-FDG PET/CT for Diagnosis of Osteosclerotic and Osteolytic Vertebral Metastatic Lesions: Comparison with Bone Scintigraphy.

18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis.

The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities.

Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.

P304

14458

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-018-32745-Z

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2018-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30262849

http://www.w3.org/2001/XMLSchema#string

P932

6160449

http://www.w3.org/2001/XMLSchema#string